Every day we get new member request from peptide sellers, I mean they're crawling out of the woods!

(Article by T Labs) “RETA's days are numbered.” “Here we go again.” “FDA just did WHAT?” “Another processor is gone.” “Don't panic... but PAY ATTENTION.” Every time I think we've reached peak insanity, this industry somehow finds another gear. 💳 Then THIS happened this week ... I'm not going to name names, but one of the largest, and arguably the most recognizable, peptide brands in this industry lost access to one of its credit-card processors. And no... They're not even one of the companies named in the Lilly lawsuits. These guys are MASSIVE. Not some website that appeared six months ago. Not some guy selling peptides on Facebook out of the trunk of the family SUV. 😂 We're talking about a major, established name that practically everybody who's been around this industry knows. If it can happen to them basically overnight, everybody in this industry should be paying attention. NOW IT'S REALLY STARTING TO HIT HOME. 🔥 And then Lilly drops THIS. Lilly filed six new federal lawsuits involving reta, including against Research Use Only peptide sellers. But believe it or not, the six lawsuits aren't even what concerns me most. ➡ Lilly says it has now: Referred 200+ individuals and companies to regulators and law enforcement Reported 14,000+ websites, advertisements, social posts and product listings Called on credit-card companies and payment processors to take action Called on shipping and logistics companies to take action Called on e-commerce platforms to take action Called on social-media companies to take action 🚨 THIS IS THE PART EVERYBODY NEEDS TO UNDERSTAND. ➡ The six lawsuits are the part everybody sees. But they're only the visible tip of something much bigger. ➡ Lilly says it has reported 14,000+ websites, advertisements, social-media posts and product listings involving reta across more than 100 countries. ➡ At the same time, Lilly says it has referred 200+ individuals and entities to the FDA, Department of Justice, state attorneys general, law enforcement and professional licensing boards.

📣 If you've watched vendors quietly pull Reta from their catalogs this week, this is why. On August 12 Eli Lilly filed six federal lawsuits and made a public push to choke off the whole gray market retatrutide supply chain. Here's what happened... ➡ PRC website credit card payment processing was shut down almost a week ago! What Lilly did: • ⁠Filed six federal lawsuits in one shot, and the mix is the tell. Four of the six are research peptide sellers running the "research use only" model, alongside a med spa and a compounding pharmacy. • ⁠Took the research supply channel to court by name for the first time, instead of just referring sellers to regulators like before. • ⁠Went after the infrastructure too, publicly calling on payment processors, credit card companies, shipping carriers, and the online platforms to cut these sellers off. • ⁠Flagged over 14,000 listings across 100+ countries and referred 200+ people and entities to the FDA, DOJ, and state attorneys general, with customs already seizing far more than it used to. ❇️ The core of the lawsuits is the claim that "research use only" is a fig leaf. Lilly's argument is that vendors put RUO on the label while selling it knowing full well it's going into people, and that the label doesn't make the sale legal when the intent is human use. The FDA already said back in June that unapproved retatrutide sold to consumers is illegal and can't be compounded. So the RUO shield the whole market leans on is being tested in a courtroom for the first time. ❇️ And none of this means Reta is junk, it's the opposite. Lilly's own trials have people losing around 28% of their body weight, it might be the strongest thing in the class, and they plan to file for FDA approval in early 2027. The crackdown is happening because it works and demand is running years ahead of approval. They're clearing the field before they launch a blockbuster. ⚠️ What it means if you research Reta: ⁠Supply tightens and prices move. More vendors will drop it the way the first ones already have!

❇️ Modern medicine is extraordinarily good at one thing: keeping sick people alive longer. It is far less good at the harder question — keeping people from getting sick in the first place. We have built an entire global healthcare infrastructure around the management of disease after it arrives: the bypass surgery after the heart attack, the chemotherapy after the tumor, the insulin regimen after the pancreas fails, the rehabilitation after the stroke. These interventions matter enormously and save millions of lives. But they are, almost without exception, responses to a failure that has already occurred. The real prize — the one longevity and peptide research is actually chasing — is preventing the failure entirely. ❇️ The Problem Is Aging Itself The chronic diseases that consume most of the healthcare system's resources — cardiovascular disease, cancer, neurodegeneration, type 2 diabetes, chronic kidney disease, osteoarthritis — are not random events. They are the predictable downstream consequences of biological aging: accumulating DNA damage, senescent cell burden, mitochondrial decline, chronic inflammation, telomere shortening, stem cell exhaustion, protein aggregation. They share root causes. Treating them one at a time — one drug for hypertension, another for blood sugar, another for joint pain — is treating the branches of the tree while the roots keep growing. Longevity research represents a genuine paradigm shift: address the root biological processes that make people susceptible to all of these conditions simultaneously, rather than waiting for each one to manifest and then managing it in isolation. The goal is not living longer in a nursing home. It is compressing morbidity — extending the period of healthy, functional life and shortening the period of decline at the end of it. More years where you can work, think, move, and contribute. Fewer years of dependence and disease management. That is a goal worth pursuing seriously. ❇️ Why Peptides Are the Right Tool for This Moment

❇️ The peptide research conversation tends to cluster around the same handful of compounds — BPC-157, TB-500, the GLP-1agonists, the well-known Khavinson series. Those are excellent compounds with excellent data, and covering them thoroughly matters. But there's a deeper layer. A set of peptides and small molecules with genuinely compelling research profiles that rarely make it into the conversation — either because they come from research traditions outside the English-speaking mainstream, because they're harder to source, or because they simply haven't had the right ambassador yet. This article is a brief tour through some of them. Consider it a reading list. ❇️ SS-31 (Elamipretide) — The Mitochondrial Membrane Guardian SS-31 is a tetrapeptide that does something no other research compound does quite as precisely: it targets cardiolipin — a unique phospholipid found almost exclusively in the inner mitochondrial membrane — and stabilizes it. Cardiolipin is essential to the architecture of the electron transport chain complexes; when it oxidizes with age, the ETC loses efficiency, proton leak increases, and mitochondrial ATP output declines. SS-31 intercalates into the inner membrane, prevents cardiolipin oxidation, and in animal studies has reversed age-related declines in mitochondrial function in heart, kidney, muscle, and brain tissue — sometimes dramatically, producing energy output in old mitochondria approaching that of young ones. It's approved under the name elamipretide for Barth syndrome (a rare cardiolipin metabolism disorder) and heart failure with preserved ejection fraction. Early human data looks promising. For researchers thinking about mitochondrial aging from the membrane architecture side — rather than the MOTS-c/Humanin signaling side — SS-31 is arguably the most mechanistically targeted tool in existence. ❇️ Dihexa — The Synapse Builder Almost Nobody Is Talking About Dihexa is a small peptide developed at Washington State University by Joseph Harding and colleagues, designed as a potentiator of hepatocyte growth factor (HGF) and its receptor c-Met — a signaling axis with profound effects on synaptogenesis, the formation of new synaptic connections in the brain. In cell-based assays, Dihexa was reported to be approximately ten million times more potent than BDNF at promoting synapse formation. That number deserves to be read slowly.